Treatment of renal failure and blood pressure

Curr Opin Nephrol Hypertens. 1997 May;6(3):237-42. doi: 10.1097/00041552-199705000-00007.

Abstract

Some of the more important advances in slowing progression of renal disease in the past few years include the following: the identification of specific racial groups, such as African-Americans and Mexican-Americans, who are at higher risk for renal disease progression than the general population; the observation that African-Americans may require lower levels of blood pressure reductions (i.e. < 125/75 mmHg) than the general population in order to achieve a similar degree of protection against renal disease progression; the understanding that angiotensin-converting enzyme inhibitors in the early stages of diabetic renal disease and nondihydropyridine calcium-channel blockers in those with established renal insufficiency from diabetes slow renal disease progression and reduce proteinuria; and lastly, aggressive blood pressure reduction in dialysis patients is associated with a reduction in cardiovascular events.

Publication types

  • Review

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Antihypertensive Agents / therapeutic use*
  • Biomarkers
  • Blood Pressure / drug effects*
  • Calcium Channel Blockers / therapeutic use
  • Cardiovascular Diseases / prevention & control
  • Diabetic Nephropathies / drug therapy
  • Diabetic Nephropathies / physiopathology
  • Diuretics / therapeutic use
  • Humans
  • Hypertension, Renal / drug therapy
  • Hypertension, Renal / physiopathology
  • Renal Insufficiency / drug therapy*
  • Renal Insufficiency / physiopathology*

Substances

  • Adrenergic beta-Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Biomarkers
  • Calcium Channel Blockers
  • Diuretics